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Abstract
 
Survivin is an inhibitor of apoptosis protein that also functions during mitosis. It is expressed in
all common tumors and tissues with proliferating cells, including thymus. To examine its role in
apoptosis and proliferation, we generated two T cell–specific survivin-deficient mouse lines with
deletion occurring at different developmental stages. Analysis of early deleting survivin mice
showed arrest at the pre–T cell receptor proliferating checkpoint. Loss of survivin at a later stage
resulted in normal thymic development, but peripheral T cells were immature and significantly
reduced in number. In contrast to in vitro studies, loss of survivin does not lead to increased
apoptosis. However, newborn thymocyte homeostatic and mitogen-induced proliferation of
survivin-deficient T cells were greatly impaired. These data suggest that survivin is not essential
for T cell apoptosis but is crucial for T cell maturation and proliferation, and survivin-mediated
homeostatic expansion is an important physiological process of T cell development.
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Introduction
 
The thymus is the major organ of T lymphocyte maturation
and differentiation. During development, T cells have to
confront sequentially fateful decisions: the pre-TCR
checkpoint, TCR 
 
  
 
chain rearrangements, positive selection,
and negative selection (1, 2). Early T cells are CD4
 
  
 
CD8
 
 
 
(double negative [DN]), which can be subdivided further
into DN1, DN2, DN3, and DN4 stages based on their
expression of CD25 and/or CD44. The first step of rear-
rangements involves TCR 
 
  
 
chain at the DN2 and DN3
stages. If successful, this results in expression of the pT
 
 
 
/
TCR 
 
  
 
chain–CD3 pre-TCR complex on the cell surface.
Subsequent rounds of proliferation between DN3 and
DN4 ensue, accompanied by differentiation into CD4
 
 
 
CD8
 
  
 
(double positive [DP]) cells. At the DP stage, TCR
 
  
 
rearrangements take place and functional TCRs can be
found on the cell surface. Most DP thymocytes, however,
die through negative selection or neglect because their
TCRs exhibit either too much or no affinity for the major
histocompatibility complex/peptides. Only relatively few
DP cells undergo positive selection and differentiate into
CD4
 
  
 
CD8
 
  
 
or CD4
 
  
 
CD8
 
  
 
(single positive [SP]) cells.
These mature cells then migrate to the peripheral immune
organs where they carry out their major function in defend-
ing the body against foreign invasion. In adult animals,
proliferation is thought to occur mainly between DN and
DP T cells, whereas little proliferation takes place in the
later stages of T cell development. In contrast, proliferation
of SP thymocytes has been seen in up to 21-d-old animals
(3, 4), the significance of which, however, has not been
fully addressed.
In addition to proliferation, programmed cell death also
plays a critical role in the development of T cells at multiple
stages. Developing DN or DP T cells are destined to die
unless a functional pre-TCR or TCR is expressed. Thy-
mocytes bearing “useless” or “self-reactive” receptors are
eliminated through an apoptotic process, thereby allowing
only 
 
 
 
3–5% thymocytes to eventually mature and be ex-
ported into the periphery. The mechanism of lymphocyte
apoptosis can be broadly divided into extrinsic and intrinsic
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pathways (5, 6). The intrinsic pathway involves the Bcl-2
and inhibitor of apoptosis protein (IAP) family members,
whereas apoptosis initiated by the death receptor comprises
the extrinsic pathway. The Bcl-2 family members are in-
volved in the process of thymocyte death by neglect and
negative selection. Overexpression of Bcl-2 leads to an en-
larged thymus and resistance of transgenic DP cells to
apoptosis, as assessed by in vitro cell culture. Mutations in
Bim, a BH3 pro-apoptotic Bcl-2 family member, or its
downstream proteins, Bax and Bak, result in defective neg-
ative selection processes (7, 8). In contrast, the role of TNF
receptor family members in T cell selection remains con-
troversial. Fas, the prototype TNF receptor family mem-
ber, is not required for negative selection, except in some
special circumstances (9, 10). TRAIL, a TNF-related
ligand, was reported recently to be important for negative
selection (11), but this could not be reproduced in another
study (12). Transgenic mice expressing a FADD dominant
negative that blocks signaling of all TNF death receptors,
exhibit no defects in negative selection (13).
Survivin, or TIAP, is a member of the IAP family (14–
16), a major class of modulators of apoptosis. IAP members
are evolutionarily conserved and in 
 
Drosophila 
 
they com-
prise the major antiapoptotic proteins. Most IAP members
inhibit apoptosis by binding to effector caspases. Release of
Smac/Diablo from mitochondria in insulted cells causes
IAPs to dissociate from the corresponding caspases, allow-
ing them to be activated by the apical caspase-9 (17, 18).
Survivin contains a single baculovirus IAP repeat and with
142 amino acids, it is the smallest IAP member. In contrast
to most IAPs, survivin does not have a RING domain at its
C terminus but instead contains a coil-coiled region that is
presumably required for its subcellular localization (19).
Survivin is ubiquitously expressed during embryonic devel-
opment, suggesting an important role in embryogenesis (20).
In normal adult tissues, survivin is expressed abundantly in
the thymus, testis, and proliferating cells. Overexpression of
survivin can protect cells from both receptor- and injury-
induced apoptosis (21–24), whereas introduction of anti-
sense, ribozyme, or dominant negative survivin leads to
spontaneous increased apoptosis (25–29). How survivin in-
hibits apoptosis, however, is controversial. Survivin has
been reported to bind to several caspases (20, 21, 30) but its
structure fails to reveal a caspase-binding pocket that is
found in other IAP family members (31). Survivin was also
shown to bind to Smac and this binding appears essential
for regulating its antiapoptotic activity (18, 32).
In addition to its purported role in apoptosis, survivin is
important for cell cycle progression. Survivin expression is
induced in the G
 
2
 
/M phase of the cell cycle (33) and inter-
estingly, it is expressed at high levels in almost all types of
human tumors in a cell cycle–independent manner (34).
The latter indicates that survivin expression is deregulated
in malignancy. Survivin has been shown to localize to cen-
trosomes, centromeres, and microtubule spindles, and in-
teracts with polymerized tubulin and Aurora B kinase, a
protein essential for cytokinesis (35, 36). Survivin-deficient
mice die in utero by day 4.5 of gestation (36, 37). Survivin-
null embryos exhibit disrupted microtubule formation and
polyploidy (36), suggesting that survivin is crucial for regu-
lation of cytokinesis. In lower eukaryotes like yeast and
 
Caenorhabditis elegans
 
, the survivin ortholog, Bir1, only
plays a role in cell cycle but not apoptosis (38–40).
To assess the potential role of survivin in apoptosis and
proliferation, we generated two lines of T cell–specific sur-
vivin-deficient mice. We used the Cre-loxP system to con-
ditionally target and inactivate the survivin gene in T cells
at various developmental stages (41). 
 
Lck-Cre
 
 and 
 
CD4-Cre
 
transgenic mice that express Cre at different DN stages
were used to delete survivin. We found aberrant thymic
development in the lck-survivin mice, whereas CD4-sur-
vivin mice exhibited normal thymic populations. How-
ever, the CD4-survivin–deficient mice have a drastic re-
duction in peripheral CD4
 
  
 
and CD8
 
  
 
T cells, which
exhibit an “immature” phenotype. Apoptosis in survivin-
deficient T cells is indistinguishable from their wild-type
counterparts but they are defective with respect to the abil-
ity to undergo proliferation. Analysis of newborn T cell–
specific survivin-deficient mice showed that their mature
thymocytes fail to populate the peripheral compartment
and this in turn results in a compensatory attempt to prolif-
erate. These data suggest that survivin does not play a ma-
jor role in inhibition of apoptosis of T cells, but rather is
crucial for their maturation, homeostasis, and proliferation
at multiple stages.
 
Materials and Methods
 
Generation of Mice with the Survivin Gene Flanked by loxP Sites.
 
We have previously prepared a targeting vector to inactivate the
survivin gene by homologous recombination in embryonic stem
(ES) cells (37). To that end, a 6.5-kb EcoRV fragment of the sur-
vivin gene encompassing all four exons was deleted and replaced
with a loxP-flanked neomycin gene cassette, which was preceded
by a unique Xho1 site. To generate a targeting vector in which
the survivin gene was intact yet flanked by loxP sites, we first
subcloned the 6.5-kb EcoRV fragment into a shuttle vector such
that an additional loxP site was placed upstream of exon 1 at the
most 5
 
  
 
EcoRV site. The resultant loxP-EcoRV fragment was
subcloned into the XhoI site of the “knockout” targeting vector,
and the correct orientation was confirmed. The new targeting
vector DNA was linearized with Not1 and electroporated into
129/SvEv ES cells (42) for selection and confirmed for homolo-
gously recombined ES cell colonies by Southern blotting using 5
 
 
 
and 3
 
  
 
probes. For the 5
 
  
 
probe, the DNAs were digested with
KpnI and EcoRV to detect a 14-kb targeting allele (see Fig. 1 B).
For the 3
 
  
 
end, the DNAs were digested with SacI and SpeI and
probed with the 3
 
  
 
external probe. The expected wild-type and
targeted alleles are 7.8 and 7.2 kb, respectively (unpublished data).
The neomycin cassette was excised in vitro by transient exposure
of positive ES cell clones to cre recombinase. Those ES cell
clones in which only the neomycin gene was excised, confirmed
by PCR and Southern blotting, were expanded for aggregation
and introduction into pseudopregnant female NIH Swiss white
mice. Three 
 
 
 
90% chimeric male offspring produced germline
transmission of the floxed survivin allele. F1 and F2 offspring
were intercrossed. Genotyping was performed on tail DNA by 
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PCR and/or Southern blotting. PCR typing was performed us-
ing oligonucleotide primer pair Adv17 (5
 
 
 
-caggccgatggtctca-
gaaata) and Adv18 (5
 
 
 
-ggtttccttcttgctattctgact), which yielded a
408-bp amplicon across the most 5
 
  
 
loxP site and a 364-bp am-
plicon from the wild-type allele. Primer pair Adv25 (5
 
 
 
-gatggt-
gatgaaactagcatctcaccctg) and Adv28 (5
 
 
 
-gcttaagtccacgtcacaata-
gagc) resulted in a 577-bp amplicon in the targeted allele across
the 3
 
  
 
loxP site and a 386-bp amplicon in the wild-type allele (see
Fig. 1 B).
 
Mouse Genotyping.
 
Mouse genotyping was performed by
PCR of the tail DNA. For genotyping Cre-deleted flox survivin
allele, three primers, Adv17, Adv25, and Adv28, were used for
PCR. For the survivin flox allele, a fragment of 577 bp was gen-
erated with the pair of primers Adv25 and Adv 28 as described
above. For the deleted allele, a fragment of 420 bp was generated
with primers Adv17 and Adv28 (see Fig. 1, A, C, and D). Geno-
typing of survivin
 
    
 
mice has been described (37).
 
Flow Cytometry Analysis.
 
Cell suspensions were prepared
from thymus, spleen, and lymph nodes. After red blood cell lysis,
cells were stained with the indicated antibodies conjugated to PE,
FITC, or tricolor (Caltag Laboratories and BD Biosciences).
Normal mouse serum was added to eliminate nonspecific stain-
ing. Cell cycle analyses were performed by first staining cells with
FITC-conjugated CD4 and CD8 antibodies. Cells were then
fixed with 70% ethanol for 2 h and digested with 500 
 
 
 
g/ml
RNase A (Sigma-Aldrich) at 37
 
 
 
C for 30 min. After washing, the
cells were stained with 50 
 
 
 
g/ml propidium iodide followed by
flow cytometric analysis (Coulter). For apoptosis assays, cells were
stained with 7-amino actinomycin D (7-AAD; Sigma-Aldrich) or
FITC–annexin V (BD Biosciences) as previously described (43).
 
Preparation of Lymphocyte Subpopulations and Western Blot Analy-
sis.
 
Thymocytes and peripheral lymphocytes were separated
into different subpopulations using a cell sorter for genotyping
and Western blot analysis. The different DN stages were identi-
fied by CD25 and CD44 staining on thymocytes gated on the
CD4
 
  
 
CD8
 
  
 
population. The purities of the separated subpopu-
lations were checked by rerunning a portion of purified cells
(they ranged from 95 to 99%). For isolation of purified CD4 or
CD8 splenocytes, biotin-conjugated CD4 and CD8 antibodies
(BD Biosciences) were used. After staining, the splenocytes were
incubated with streptavidin microbeads (Miltenyi Biotec) at 4
 
 
 
C
for 20 min followed by repeated washing. The splenocytes were
run on a MACS cell sorter (Miltenyi Biotec) to isolate CD4
 
  
 
or
CD8
 
  
 
lymphocytes. Protein lysates were prepared by lysing the
cells in a hypotonic buffer as previously described (44). Cytosolic
and nuclear fractions were prepared and separated on a 15% SDS-
PAGE. Western blot analysis was performed according to a stan-
dard protocol using a purified rabbit anti–survivin antibody (22).
 
Apoptosis Assay.
 
Primary thymocytes and peripheral lympho-
cytes were prepared from thymus, spleen, and lymph nodes and
stained with 7-AAD as well as PE anti-CD4 and tricolor anti-
CD8 on ice for 30 min. Alternatively, cells were stained with
FITC–annexin V. Stained cells were then subjected to flow cy-
tometry analysis. For induction of apoptosis, 5 
 
  
 
10
 
6
 
/ml thy-
mocytes or peripheral lymphocytes in 10% FBS/RPMI 1640 were
treated at various time points at 37
 
 
 
C with either 1 
 
 
 
g/ml hamster
anti–Fas antibody (BD Biosciences), 50 ng/ml recombinant FasL
(Qbiogene), 50 nM dexamethasone, a combination of 0.5 mg/ml
plate-bound anti-CD3 (500A2) and 0.5 mg/ml anti-CD28 (37N)
antibodies, 2 mg/ml Con A (Sigma-Aldrich), or a combination of
10 ng/ml PMA (Calbiochem) and 1 mM ionomycin (Calbio-
chem). Treated cells were then stained with 7-AAD, PE anti-
CD4, and tricolor anti-CD8 followed by flow cytometry analysis.
 
Carboxy Fluorescein Diacetate Succinimidyl Ester (CFSE).
 
10
 
6
 
splenocytes/ml were labeled with 10 
 
 
 
M CFSE in PBS/0.1% bo-
vine serum albumin at 37
 
 
 
C for 10 min. After washing twice with
10% FBS/RPMI 1640, splenocytes were stimulated with either
Figure 1. Generation of T cell–specific survivin-deficient mice. (A) A
schematic diagram of the survivin gene locus and its various alleles. The
targeting construct has three loxP sites (triangles) flanking the four survivin
exons (boxes) and the neomycin gene. After selecting the cells with the
appropriate targeting allele, the neomycin gene was removed by transfecting
a cre-expressing plasmid. The survivin flox allele mice were then generated
and crossed to lck-cre or CD4-cre according to the scheme described in
Results, to generate lck-survivin– or CD4-survivin–deficient mice. K, KpnI;
S, SacI; E, EcoRV. Horizontal arrows denote the approximate location of
the oligonucleotides used for genotyping and analysis in C (Adv17,
Adv25, and Adv28). (B) Southern blot and PCR analysis of the flox
survivin allele. Left: Southern blot analysis of the ES cells containing loxP
sites in the survivin locus. The DNAs were digested with a combination
of KpnI and EcoRV and hybridized with a 5  probe as depicted in A. The
presence of a 14-kb band is indicative of the correct targeted allele. Right:
PCR analysis of the resulting survivinflox/  mice after the neomycin gene
has been removed (3  flox sites). (C) PCR analysis of the survivin-deleted
allele in various T cell DN sub-populations. The different DN subpopu-
lations were sorted based on their CD25 and CD44 expression: DN1
(CD44  CD25 ), DN2 (CD44  CD25 ), DN3 (CD44  CD25 ), DN4
(CD44  CD25 ). PCR analysis using three oligonucleotides (Adv17,
Adv25, and Adv28 in A) flanking the survivin flox allele was conducted
to analyze for the presence of the survivin flox allele (a 577-bp product of
Adv25 and Adv28) or the deleted allele (a 420-bp of Adv17 and Adv28).
(D) PCR analysis of the survivin-deleted allele in splenic CD4  T cell
populations. Splenic T cells were stained with anti-CD4 and CD8 anti-
bodies and sorted by flow cytometry (99% pure) and subjected to PCR
analysis as described in C above. (E) Western blot analysis of survivin
expression in purified DP thymocytes. Two survivin isoforms were detect-
able in the wild-type thymocytes. C, cytoplasmic extracts; N, nuclear
extracts. Western blotting using anti– -tubulin antibodies was performed
as a loading control. 
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0.5 mg/ml plate-bound anti-CD3 and 0.5 mg/ml anti-CD28 an-
tibodies, 2 mg/ml Con A, or a combination of 10 ng/ml PMA
and 1 mM ionomycin for 4 d at 37
 
 
 
C as previously described
(45). The stimulated splenocytes were harvested from culture
plates and then stained with PE anti-CD4 antibody. CD4
 
  
 
gated
lymphocytes were further analyzed for CFSE fluorescence by
flow cytometry. Splenocytes were stimulated as described above
for cell cycle analysis, except the treatments lasted for 48 h. Stim-
ulated cells were then stained with FITC anti-CD4
 
  
 
and CD8
 
 
 
antibodies, fixed with ethanol, and stained with propidium iodide
for flow cytometric analysis on CD4
 
  
 
or CD8
 
  
 
gated lympho-
cytes.
 
5-Bromo-2-Deoxyuridine (BrdU) Labeling.
 
For DNA incorpo-
ration analysis of thymocyte and peripheral T cells, adult (6–8
wk) or newborn (5–7 d) mice received two intraperitoneal injec-
tions of BrdU (Sigma-Aldrich) at 2-h intervals as previously de-
scribed (41). For each injection, 1 and 0.2 mg BrdU for adult and
newborn mice were used, respectively. Mice were killed 1 h after
the last injection and thymi and spleens were taken out for cell
preparation. Cells were first stained with PE anti-CD4 and tri-
color anti-CD8 antibodies. After fixing and permeabilization,
cells were stained with FITC anti-BrdU antibody (BD Bio-
sciences) and subjected to flow cytometry.
 
7-AAD/BrdU Analysis.
 
BrdU and cell cycle studies were
performed according to the published protocol (46) with some
modifications. Newborn mice received either four intraperitoneal
injections of 0.2 mg BrdU once every 6 h or 3-h BrdU labeling
with two injections as described above. Thymocytes and spleno-
cytes were then stained with either PE anti-CD4 or PE anti-CD8
antibodies. After two washes, cells were fixed with 75% ethanol
and then permeabilized with 1% paraformaldehyde and 0.01%
Tween 20. After digestion with 100 Kuntz/ml DNase I (Sigma-
Aldrich), cells were stained with FITC anti-BrdU antibody at
 
4
 
 
 
C for 30 min. For 7-AAD staining, the cells were washed and
incubated with 500 
 
 
 
g/ml RNase A (Sigma-Aldrich) at 37
 
 
 
C for
30 min followed by staining with 7-AAD at 4
 
 
 
C for 30 min.
 
Results
 
Generation of T Cell–specific Survivin-deficient Mice.
 
Three steps were involved in the generation of T cell–spe-
cific survivin knockout mice. First, the wild-type 
 
survivin
 
exons were replaced by the loxP-flanked gene through spe-
cific targeting, resulting in 
 
survivin
 
flox/
 
 
 
 
 
mice (Fig. 1, A and
B). Second, 
 
lck-cre
 
 and 
 
CD4-cre
 
 mice (41) were crossed with
 
survivin
 
 
 
/
 
 
 
 
 
mice in which all four exons have been deleted
in one of the 
 
survivin
 
 alleles (37) to obtain 
 
lck-cre/survivin
 
 
 
/
 
 
 
or 
 
CD4-cre/survivin
 
 
 
/
 
  
 
mice. Lastly, 
 
survivin
 
flox/
 
 
 
 
 
mice were
bred to 
 
lck-cre
 
/
 
survivin
 
 
 
/
 
 
 
 
 
or 
 
CD4-cre
 
/
 
survivin
 
 
 
/
 
 
 
 
 
mice to
generate 
 
lck-cre/survivin
 
flox/
 
 
 
 
 
and 
 
CD4-cre/survivin
 
flox/
 
 
 
 
 
mice,
respectively (henceforth termed lck-survivin and CD4-sur-
vivin). Their survivin expressing littermates (
 
survivinflox/ ,
cre /survivin / , or cre /survivinflox/ ) were used as controls.
Lck-Cre and CD4-Cre transgenic mice express the Cre re-
combinase in DN2 and DN3 T cells, respectively (41, 47).
Recombination of the loxP sites is usually complete by
DN3 for lck-Cre mice and DN4 for CD4-Cre mice. As
TCR   checkpoint and proliferation occur between DN3
and DN4, these two lines of mice offer us the opportunity
to assess the requirement of survivin for early   checkpoint
and late T cell events in DP and mature T cells.
Survivinflox/ , lck-survivin, and CD4-survivin mice were
all born alive and appeared healthy. Thymocytes were col-
Figure 2. Analysis of lck-survivin mice. (A) The absolute
cell numbers of DN, DP, SP (CD4  CD8  or CD8 
CD4 ), and peripheral T cells in lck-survivin mice and the
littermate controls (n   12). (B) CD4/CD8 ratio of thy-
mocyte SP and peripheral T cells. (C) Left: CD4 versus
CD8 flow cytometric analysis of lck-survivin thymocytes
and the littermate controls. Middle: Flow cytometric analysis
of lck-survivin thymocytes gated on CD4  CD8  DN
cells. Numbers indicate the percentages of the corresponding
populations. Right: Flow cytometric analysis of CD25 
DN thymocytes from lck-survivin and control thymocytes.
Numbers indicate the percentages of the corresponding
population. E, small cells; L, large cells.Xing et al. 73
lected from 4–8-wk-old mice and separated into DN1,
DN2, DN3, and DN4 subpopulations based on their
CD44 and/or CD25 expression ( 96% purity). PCR anal-
ysis with the appropriate oligonucleotides can detect a 577-
bp product that represents the undeleted loxP survivin al-
lele and a 420-bp product that represents the deleted allele.
As shown in Fig. 1, C and D, deletion starts at DN3 for
CD4-survivin and is complete by the DN4 stage. At this
stage, the upper 577-bp product is undetectable. In lck-
survivin mice, however, deletion initiates earlier at the
DN2 and increases through the DN3 and DN4, but the
upper loxP wild-type band remains in DN4 and in mature
peripheral T cells (Fig. 1, C and D). This may reflect pref-
erential proliferation and differentiation of those thy-
mocytes with incomplete deletion of survivin. Using the
identical lck-cre transgenic line, complete deletion was de-
tected in Notch-deficient mice (47). To see whether the
extent of DNA deletion corresponded to the loss of sur-
vivin protein, we performed Western blot analysis to detect
survivin in the DP population. No survivin was detected in
DP thymocytes from CD4-survivin mice (Fig. 1 E). How-
ever, consistent with the PCR results, a small amount of
survivin protein was seen in lck-survivin DP thymocytes
(Fig. 1 E).
Aberrant Thymic Development in lck-survivin Mice. When
4–8-wk-old lck-survivin mice were analyzed, we found
their thymic cellularities to be about one eighth of those in
their littermate controls (1.38   107   0.39 vs. 11.33  
107   1.22). Spleen weight and total cell numbers of lck-
survivin mice were comparable to the wild-type controls,
whereas the lymph nodes were 50% smaller (2.06   107  
0.28 vs. 4.64   107   0.78). T cell subpopulations in thy-
mus, spleen, and lymph nodes were examined. Severe im-
pairment of T cell development was observed in lck-sur-
vivin mice with most of the thymocytes being DN,
indicating that the progression of thymocytes from DN to
DP stages was blocked (Fig. 2). This is also reflected by the
decrease in the absolute cell number of DP in lck-survivin
mice (Fig. 2 A). Interestingly, in spleens and lymph nodes,
mature T cells from lck-survivin mice were reduced but
not drastically so (Fig. 2 A). This is most likely due to nor-
mal development of survivin  cells. Indeed, peripheral T
cells of lck-survivin mice contain significant undeleted flox
survivin allele (Fig. 1 D). The ratio of CD4 to CD8 T cells
was comparable to that of the wild-type controls and as ex-
pected (Fig. 2 B), the B cell and macrophage populations in
lck-survivin mice were not affected (unpublished data).
To examine the DN thymocytes in more detail, we
stained them with CD44 and CD25 antibodies. lck-sur-
vivin thymocytes exhibited a lower percentage of DN4
(CD44  CD25 ), with a corresponding increase in DN3
(CD44  CD25 ) cells (Fig. 2 C, middle). This indicates
that loss of survivin affected DN3 to DN4 proliferation
stages of T cell development. To see if pre-TCR signaling
is intact, we gated the DN CD25  cells and separated them
into small (E) and large (L) cells. Previous studies have
shown that the E cells consist of mostly G0/G1  cells,
whereas the L cells are mostly cycling, having received the
pre-TCR signals (48, 49). Cells from lck-survivin mice ex-
hibit a larger percentage of L cells (Fig. 2 C, right), suggest-
ing that pre-TCR signals are intact in these cells. The in-
creased number of L cells suggests that loss of survivin does
not affect the G1 to S checkpoints but are arrested later in
the cell cycle.
Normal Thymic Development but Reduced Peripheral T Cells
in CD4-survivin Mice. In contrast to lck-survivin mice, the
thymic cellularities in CD4-survivin mice were similar to
those of their littermate controls (14.55   2.48   107 vs.
18.06   1.46   107). There were also no significant differ-
ences in the total cell numbers of spleens and lymph nodes
of CD4-survivin and control mice (4.28   0.62   107 vs.
4.82   0.45   107 for lymph nodes and 12.28   2.35   107
vs. 14.81   2.61   107 for spleen). Flow cytometry analysis
using CD4, CD8, and CD3 antibodies showed a normal
profile and comparable absolute cell numbers of DN, DP,
and SP thymocytes from CD4-survivin mice and their con-
trol littermates (Fig. 3 and unpublished data). The difference
in the phenotype between CD4-survivin and lck-survivin
mice is most likely due to the timing of survivin gene dele-
tion and the fact that pre-TCR–mediated proliferation takes
place between DN3 and DN4 stages (48). Although dele-
Figure 3. Analysis of CD4-survivin mice. (A) The absolute cell numbers
of DN, DP, SP (CD4  CD8  or CD8  CD4 ), and peripheral T cells
in 4–8-wk-old CD4-survivin mice and the littermate controls (n   14).
(B) CD4/CD8 ratio of thymocyte SP and peripheral T cells. (C) CD4
versus CD8 flow cytometric analysis of CD4-survivin thymocytes and the
littermate controls. Numbers indicate the percentages of the corresponding
T cell populations.Survivin in T Cell Development and Maturation 74
tion in lck-survivin starts early, survivin deletion in CD4-
survivin mice does not start until DN3 and is complete only
in DN4 (see above) and hence most DN3 cells still express
survivin required for DN3 to DN4 proliferation.
Although the numbers of DP and SP thymocytes in
CD4-survivin mice were normal, it was surprising to note
that the mature T cells in the spleen and lymph nodes were
reduced significantly (Fig. 3 A, right). The reduction was
particularly severe for CD8  CD4  T cells. This is reflected
in the ratio of CD4 to CD8 T cells, which is normally 2:1.
In CD4-survivin peripheral organs, the ratio was  4:1
(Fig. 3 B).
Survivin-deficient T Cells in Periphery Are Less Mature.
The apparent reduction of peripheral T cells in CD4-sur-
vivin mice might be due to increased apoptosis or lack of
proliferation (see below). We reasoned that if apoptosis
were involved, the number of peripheral T cells in younger
survivin-deficient animals would be the same as in the
wild-type controls. Once in the periphery, they would
then gradually disappear. In cases where mature T cells
were depleted of their TCR   gene, CD8  cells die with a
half-life of 16 d, whereas CD4  cells die with a half-life of
46 d (50). Staining with annexin V did not show any in-
crease in apoptosis of the T cells of newborn or adult sur-
vivin-deficient mice (see below). In contrast, flow cyto-
metric analysis showed that the reduction of peripheral T
cells in CD4-survivin mice was even more pronounced in
newborn (0–1-wk-old) mice. Although the subpopulations
and cell numbers of the newborn survivin-deficient thy-
mocytes are identical to their littermate controls (Fig. 4 A),
splenic and lymph node CD4  CD8  and CD4  CD8  T
cells were reduced by up to 14-fold (Fig. 4, A and B; CD4-
survivin mice: CD4 cells: 2.68   0.55   105, CD8 cells:
0.94    0.21    105; wild-type littermate controls: CD4
cells: 27.05   1.71   105, CD8 cells: 13.20   0.49   105).
As proliferation of SP thymocytes is known to occur be-
tween 1 and 21 d after birth (3), these data suggest that sur-
vivin deficiency affects this proliferative step, leading to a
reduced number of peripheral T cells.
To examine the activation status after homeostatic pro-
liferation and to see if peripheral CD4  CD8  and CD4 
CD8  from CD4-survivin mice are phenotypically mature,
staining using several activation and maturation markers
was performed. These markers include CD25 IL-2R  and
CD69, which is transiently elevated in positively selecting
T cells and heat-stable antigen (HSA or CD24), which is
down-regulated as T cells mature. No significant differ-
ences in CD69 and CD25 levels on the thymocytes and
unstimulated peripheral T cells were observed between
CD4-survivin mice and their littermate controls (unpub-
lished data and see below). However, a significant propor-
tion of peripheral T cells in CD4-survivin mice were
HSA , whereas wild-type animals have few HSA  T cells
in the periphery. In newborn mice, HSAhigh CD8  T cells
were nearly double that of the littermate controls (Fig. 4 C,
left). In older animals, the difference is more pronounced.
Although 5-wk-old wild-type animals contain few HSA 
T cells, CD4-survivin mice have significant numbers of
HSA  peripheral T cells. This is particularly pronounced in
the CD8  CD4  population, where close to 40% of the
cells are HSA  (Fig. 4 C). Some of these differences in the
HSA levels can also be detected in the SP thymocyte popu-
lation (unpublished data). These data suggest that survivin-
deficient peripheral T cells are phenotypically semimature.
They are also functionally immature as stimulation through
their TCR complex did not lead to up-regulation of the
activation marker CD25 (IL-2R ; Fig. 4 D).
Survivin-deficient T Cells Do Not Exhibit Increased Sensi-
tivity to Apoptotic Stimuli. No massive cell death was ob-
served in CD4-survivin DP thymocytes. Staining of thy-
Figure 4. Reduced number of periph-
eral T cells in young mice and their ele-
vated HSA level. (A) The absolute cell
numbers of DP, SP (CD4  CD8  or
CD8  CD4 ), thymocytes, and periph-
eral T cells in newborn CD4-survivin
mice and the littermate controls (n   5).
(B) Representative flow cytometric profile
of splenocytes from 0–1-wk-old CD4-
survivin mice. The experiments have
been repeated at least three times with
similar findings. (C) CD8 versus HSA
flow cytometric profile of peripheral T
cells from CD4-survivin and control
littermates. (D) Impaired CD25 activa-
tion marker in CD4-survivin peripheral
T cells. Splenic cells from CD4-survivin
mice and their littermate controls (WT)
were stimulated with anti-CD3/CD28
antibodies for 18 h and stained with
anti-CD4 and anti-CD25 antibodies. The
CD4  gated cell profiles are shown here.Xing et al. 75
mocytes or peripheral T cells with 7-AAD or annexin V
did not reveal any significant changes in the percentage of
apoptotic cells (Fig. 5 and unpublished data). Differentia-
tion into SP thymocytes also proceeds normally, suggesting
that loss of survivin does not affect positive selection and
steady-state apoptosis in vivo. To examine the process of
death by neglect and induced cell death in the absence of
survivin, we examined thymocytes and peripheral T cells
of CD4-survivin mice for their propensity to undergo apop-
tosis and in response to outside stimuli. Baseline apoptosis
ex vivo of cells from CD4-survivin and heterozygous con-
trols is similar. As shown in Fig. 5, the absence of survivin
has no effect on the propensity of thymocytes to undergo
apoptosis in vitro. CD4-survivin–deficient thymocytes cul-
tured in vitro for 12 h die at the same rate as survivin  thy-
mocytes. Similar results were also found when thymocytes
were stimulated to undergo apoptosis by addition of an an-
tibody specific to Fas, dexamethasone, etoposide, or a com-
bination of PMA and ionomycin (Fig. 5 A and unpublished
data). No differences were observed either when soluble
FasL recombinant protein was added for a different period
of time (Fig. 5 B). At a higher dose of dexamethasone, pe-
ripheral T cells undergo apoptosis. Survivin-deficient pe-
ripheral cells showed the same propensity for dexametha-
sone- or etoposide-induced cell death as the wild-type cells
(Fig. 5 C). As expected, the addition of anti-CD3/CD28
antibodies had no effect on apoptosis of peripheral T cells.
We conclude that survivin is not essential for the inhibition
of apoptosis in T lymphocytes.
Proliferation and Cell Cycle Progression Are Blocked in Sur-
vivin-deficient T Cells. The preceding data in lck-survivin
mice suggest that they have a defect in T cell proliferation
associated with an early developmental checkpoint. To de-
termine the requirement for survivin in mature T cells, we
prepared splenocytes or lymph node cells from CD4-sur-
vivin–deficient and control mice, labeled them with CFSE,
and cultured them at 37 C for 4 d. Aliquots were treated
with anti-CD3/CD28, Con A, or PMA/ionomycin to in-
duce proliferation. These cells were then labeled with anti-
CD4 antibody and the incorporation of CFSE was used to
assess cell proliferation and cell division. As shown in Fig. 6
A, although wild-type control cells underwent several
rounds of division as evidenced by the decreasing CFSE
peaks, survivin-deficient T cells failed to complete even
one division. The addition of the strongly mitogenic
PMA/ionomycin also failed to induce cell division.
To identify which step of cell cycle progression is af-
fected, a similar experiment was performed, but the cells
were stained with propidium iodide to assess DNA con-
tent. As shown in Fig. 6 B, the loss of survivin led to de-
creasing S phase. This was more evident in T cells from
newborn animals (Fig. 6 B). When exposed to PMA and
ionomycin, survivin-deficient T cells accumulated in the
G2/M phase (Fig. 6 B). However, in cells stimulated with
Con A, survivin-deficient cells did not accumulate at the
G2/M phases but seemed to exhibit defects at the S phase.
In vivo BrdU labeling studies of homeostatic proliferating
thymocytes indicated that survivin deficiency did not lead
to a G2/M block and resulted in an incomplete S phase
(see below). These data suggest that in addition to the as-
sociation with Aurora B mitotic kinase (35), which is re-
quired for cytokinesis, survivin might also participate in
the replication checkpoint by binding with a yet to be
identified protein.
Expansion of SP Thymocytes for Peripheral Homeostasis.
To investigate further the mechanism underlying the low
T cell number in the periphery despite a normal thy-
mocyte profile in survivin-deficient mice, we conducted
BrdU labeling experiments in newborn and adult mice to
measure the rate of DNA synthesis. BrdU was injected in-
traperitoneally into newborn and adult mice and the ex-
tent of BrdU incorporation into recently replicating thy-
mocytes and peripheral T cells was assessed 3 h later.
Although adult thymocytes did not proliferate and hence
contained few BrdU  cells, thymocytes from newborn
mice exhibited a significant number of BrdU  cells (Fig. 7
A). This is consistent with the notion that SP thymocytes
undergo homeostatic proliferation in newborn animals be-
fore export to the periphery (3). As the peripheral com-
partment is filled up, the rate of proliferation drops. In sur-
Figure 5. Apoptosis proceeds normally
in the absence of survivin. (A) Thy-
mocytes from CD4-survivin and their
littermate controls were incubated for
12 h in the absence of any stimuli or
with anti-Fas antibody, dexamethasone
(dex), or a combination of PMA phorbol
ester and ionomycin (n    4). Percent
apoptotic cells were measured by staining
with 7-AAD. The same experiments have
been performed with annexin V with
similar results. 0, unstimulated fresh thy-
mocytes. (B) Percent thymocytes that
were undergoing apoptosis were mea-
sured after 12, 24, or 48 h of incubation
with 50 ng/ml soluble FasL recombinant
protein (Qbiogene). Thymocytes were
taken from CD4-survivin mice or their wild-type littermates (WT). (C) Percent apoptotic CD4 splenic T cells were measure by 7-AAD staining after 12 h of
incubation in the absence ( ) or presence of either 1  M dexamethasone (dex), 10  g/ml etoposide (ET), or a combination of anti-CD3/CD28 antibodies.Survivin in T Cell Development and Maturation 76
vivin-deficient mice, however, BrdU incorporation was
not diminished. If any, a reproducible increase in BrdU la-
beling was detected instead (Fig. 7 A). This effect was
more pronounced in CD8  cells than CD4  cells (percent
BrdU incorporation in CD8   SP cells: CD4-survivin:
27.42   1.78%, wild-type littermates: 18.2   2.86%; per-
cent BrdU incorporation in CD4  cells: CD4-survivin:
7.53   3.94%, wild-type littermates: 5.495   1.03%; n  
4). These observations were substantiated by FACS® anal-
ysis of the side and forward scatter plots of these survivin-
deficient SP thymocytes, which revealed a similar increase
in the proportion of larger than normal CD8  and CD4 
SP thymocytes (Fig. 7 B). Interestingly, splenic CD8 
cells, which usually are not cycling, incorporated BrdU
when survivin was deleted (Fig. 7 A, right). These data
suggest that survivin-deficient T cells could synthesize
DNA and indeed replicated at a higher rate than wild-type
T cells, but CFSE and propidium iodide analysis suggests
that they could not complete the cell cycle.
To further examine the cell cycle status of survivin-defi-
cient thymocytes in vivo, 7-AAD was used to assess thy-
mocyte DNA content after BrdU injection of newborn an-
imals. Mice were analyzed 3 h after injection or after 25 h
with four BrdU injections. As shown in Fig. 7 C, the BrdU
versus 7-AAD profiles of CD8  SP cells and some DN thy-
mocytes (DN cells are the same between CD4-survivin and
their wild-type littermates) revealed thymocytes in the G1/
G0 state (BrdU /7-AADlow) and some in the G2/M state
(BrdU /7-AADhigh). Proliferating cells were BrdU  and
exhibited an increasing amount of DNA content as they
progressed through the different states of the cell cycle.
Survivin-deficient thymocytes showed increased BrdU in-
corporation, even when labeled only for 3 h (unpublished
data), suggesting that they have no problem at the G1 to S
checkpoint. In contrast to wild-type cells, however, they
accumulate at the state between 2N and 4N DNA contents
(Fig. 7 C), indicating that they are blocked at the S phase of
the cell cycle, before cells have undergone mitosis.
Figure 6. Defective cell cycle progression of survivin-
deficient T cells. (A) CFSE incorporation of Con A or
PMA/ionomycin-stimulated T cells from adult animals.
Numbers indicate the number of cell divisions of stimulated
T cells. (B) Propidium iodide staining of PMA/ionomycin
or Con A–stimulated T cells from adult or newborn mice.
The experiments have been repeated more than three
times with similar results.Xing et al. 77
Discussion
We initiated our studies of survivin in T cell develop-
ment with the notion that this unique IAP might play a
dual role in proliferation and apoptosis. Based on the obser-
vation that weaker cells are purged actively during devel-
opment, Raff (51) and Abrams (52) proposed the existence
of a class of proteins with the characteristics of “prolifera-
tion–apoptosis coupler.” These types of protein are essen-
tial for an organism as they balance the process of prolifera-
tion versus apoptosis and can signal the cells to die if
mitogen signals are not properly received. One such exam-
ple is FADD, an adaptor protein for the TNF death recep-
tor family. Cells with FADD deficiency are not only defec-
tive in TNF death receptor-mediated apoptosis, but also
exhibit proliferation defects (53). The regions involved in
apoptosis and proliferation have been mapped to two sepa-
rate domains in FADD (45). Based on previously published
work, survivin could also be a proliferation–apoptosis cou-
pler. Survivin is expressed highly during the G2/M phases
of the cell cycle and associates with the microtubule in the
centrosomes (33). Loss of survivin expression by antisense
oligonucleotides or disruption of survivin–microtubule in-
teraction in HeLa cells leads to increased apoptosis and cell
cycle arrest (25, 33). Survivin, caspase-3, and p21 cell cycle
inhibitor were found to colocalize to centrosomes and per-
turbation of survivin expression by antisense technology
led to increased caspase-3 activity and cytokinesis dysfunc-
tion (25, 33).
In contrast to the results obtained using antisense tech-
nology, however, here we show that survivin is not a pro-
liferation–apoptosis coupler in vivo, at least in T cells. Sim-
ilar to FADD deficiency (43, 53), the absence of survivin in
developing T cells leads to a block in the DN to DP transi-
tion, and mature survivin-deficient T cells exhibit cell cycle
defects at multiple stages. Interestingly, the block of DN T
cells in lck-survivin mice occurs at a later stage than
FADD-deficient mice. DN3 L cells can still be found in the
absence of survivin, suggesting that FADD functions up-
stream of survivin (45, 53). In contrast to FADD, loss of
survivin has no effect on cell death in T cells. It is possible
that redundant functions of other antiapoptotic proteins in
T cells can compensate for the loss of survivin. Alterna-
tively, survivin does not have a strong antiapoptotic activity
in vivo. Consistent with this, loss of function mutation of
the survivin ortholog in Caenorhabditis elegans does not af-
fect apoptosis, but exhibits defective cytokinesis (39, 40).
In addition to its role in early T cell development, sur-
vivin is also surprisingly essential for maturation and ho-
meostasis of SP T cells. 0–8-wk-old CD4-survivin mice
Figure 7. BrdU incorporation study of CD4-survivin–
deficient mice. (A) BrdU labeling of SP thymocytes
and peripheral T cells from CD4-survivin mice and
their littermate ( / ) controls. Mice were injected
intraperitoneally with BrdU and 3 h later flow cyto-
metric analyses were conducted for the respective T
cell populations: CD4 or CD8 SP thymocytes and
spleen CD8  cells. (B) Side and forward scatter analysis
of CD4 or CD8 SP thymocytes from CD4-survivin
and littermate ( / ) controls. The percentages of the
large (L) cells are indicated. (C) Mice were injected
with BrdU every 6 h in a 25-h period before their thy-
mocytes were harvested and stained with either anti-
CD4 or anti-CD8 antibodies followed by anti-BrdU
antibodies and 7-AAD. The BrdU versus 7-AAD
profiles of CD4  gated thymocytes, which include
CD8  CD4  SP and DN cells, are shown. Similar find-
ings were also observed for CD8  gated thymocytes.Survivin in T Cell Development and Maturation 78
have normal thymic profiles and cell numbers, but their pe-
ripheral T cells are greatly reduced. This is especially true
for CD8  CD4  cells, but a similar situation was also seen
for the CD4  CD8  population. The effect is more pro-
nounced in newborn animals. Although the proliferation
stage at the DN3 to DN4 transition has been well charac-
terized, the requirement of proliferation at the later stages
of T cell development remains unclear. Proliferation of SP
cells before migration to the peripheral tissues takes place
actively early in life up to 21 d of age (3, 54–56). Adult an-
imals exhibit some but little SP proliferation (3, 4, 57).
Here we show that the proliferation in newborn animals is
essential for complete T cell maturation and peripheral T
cell compartment. Survivin-deficient peripheral T cells are
defective in cell cycle progression and exhibit an immature
T cell phenotype. The large size and increased number of
thymocytes with  2 N DNA content in newborn sur-
vivin-deficient mice suggest that the G1 to S checkpoint is
not affected and the block occurs at the later phases of the
cell cycle. BrdU  cells are increased in these cells after
BrdU labeling experiment, suggesting that normal homeo-
static negative feedback is being affected in the absence of
survivin. The presence of mature T cells in the peripheral
compartment is known to negatively regulate proliferation
of SP thymic cells (54). In bone marrow chimera experi-
ments where mature lymph node T cells were mixed with
the bone marrow cells before transfer, proliferation of do-
nor-derived SP thymocytes 18 d after transfer was inhibited
(54). Thus, in survivin-deficient mice, the normal homeo-
static proliferation to fill up the lymphopenic newborn pe-
ripheral compartment is severely compromised. This in
turn contributes to a compensatory increase in the number
of cycling thymic cells. These data underline the impor-
tance of proliferation after T cells have undergone positive
selection in neonates, where the process of homeostatic ex-
pansion is crucial for the final stages of T cell development.
Interestingly, there seems to be more than one prolifera-
tive block for survivin-deficient T cells. In vitro, PMA/
ionomycin-stimulated survivin-deficient lymphocytes ac-
cumulated at the G2/M phase, in accordance with the re-
sults shown by others in tumor cell lines and embryos (33,
36, 58). However, our 7-AAD/BrdU labeling data surpris-
ingly indicated that thymocyte proliferation is blocked at
the S phase. Con A–stimulated peripheral survivin /  T
cells similarly showed an S phase block (Fig. 6). The differ-
ence could be explained by the strong signals conferred by
PMA/ionomycin that somehow bypass the S phase block
normally seen in milder or physiological conditions. Poly-
ploidy of survivin-deficient cells was described previously
for survivin /  embryos and HeLa cells (36, 58). This was
the result of some survivin-deficient cells exiting mitosis
without proper chromosome segregation. Consistent with
an earlier block of survivin-deficient T cells in vivo, how-
ever, little or no polyploidy cells were detected in CD4-
survivin– or lck-survivin–deficient mice (Fig. 6 and un-
published data). Most survivin-deficient peripheral cells
presumably were exported from the thymus without un-
dergoing proliferation, consistent with the view that thy-
mic SP proliferation is not required for export but is part of
homeostatic expansion to fill the “lymphopenic” neonatal
peripheral compartment.
Mature T cell homeostatic expansion has been studied in
the past by transferring small numbers of mature T cells
into lymphopenic hosts (either RAG-1 /  or SCID mice).
Upon expansion, they express CD44 and acquire a mem-
ory-like phenotype. Homeostatic proliferation requires
TCR signals, IL-7, and possibly IL-15 (59–61). Spleen and
lymph nodes of newborn mice are “empty” and support
lymphopenia-induced proliferation (55, 62). Naive T cells
transferred to newborn animals proliferate with the same
requirement for MHC/peptide and acquisition of the
CD44 memory marker as homeostatic proliferation in
adult lymphopenic hosts (55, 62, 63). Survivin is most
likely required for lymphopenic proliferation as well be-
cause newborn mice are essentially lymphopenic and stim-
ulation of mature T cells in vitro with anti-TCR antibod-
ies did not result in cell division. We showed that
homeostatic thymocyte proliferation is blocked in vivo in
the absence of survivin despite an enhanced attempt to
proliferate. Increased BrdU incorporation was also de-
tected in the splenic T cells of survivin-deficient mice, sug-
gesting that these cells attempt to proliferate to compensate
for the lack of peripheral T cells. Further studies will be
necessary to understand how survivin-mediated prolifera-
tion of neonatal T cells is regulated and how peripheral T
cell homeostasis is achieved.
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